Hlib Chabaniuk

Biomea Fusion to present new icovamenib data at American Diabetes Association event

Biomea Fusion to present new icovamenib data at American Diabetes Association event
Biomea Fusion brings new diabetes data

Biomea Fusion announced that three abstracts have been accepted for poster presentation at the American Diabetes Association 86th Scientific Sessions scheduled for June 5–8 in New Orleans.

According to the company, these presentations will deliver new data on their investigational therapy icovamenib, covering applications in both type 1 and type 2 diabetes. This move underscores Biomea Fusion intent to advance innovation in diabetes research by sharing early-stage findings with the wider medical and scientific community.

Biomea Fusion has previously reported that diabetes remains poorly controlled in many patients, highlighting unmet needs in current treatment options (link). The company recently began enrolling participants in the COVALENT-212 clinical trial to study icovamenib in type 2 diabetes (link). These efforts come as Biomea Fusion continues to advance clinical research for new diabetes therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.